Screening for Breast Cancer

When to Screen in Obstetrics and Gynecology

Volumn , Issue , 2006, Pages 591-602

  Fracheboud, Jacques ^a   de Koning, Harry J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747886834     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0300-7.50053-3     Document Type: Chapter

References (49)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Pisani P, Bray F, Parkin DM Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002, 97:72-81.
3. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents 2000, VIII:1-781. IARC Press, Lyon.
4. Fracheboud J, Otto SJ, van Dijck JAAM, et al. Decreased rates of advanced breast cancer due to mammography screening in the Netherlands. Br J Cancer 2004, 91:861-867.
5. Liberman L Breast cancer screening with MRI: what are the data for patients at high risk?. N Engl J Med 2004, 351:497-500.
6. IARC Handbooks of Cancer Prevention: Breast Cancer Screening 2002, 7. IARC Press, Lyon.
7. Botha JL, Bray F, Sankila R, et al. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003, 39:1718-1729.
8. de Koning HJ Why improvement in survival of screen-detected cases is not necessarily equivalent to benefit?. Breast 2003, 12:299-301.
9. Sant M, Allemani C, Berrino F, et al. Breast carcinoma survival in Europe and the United States. Cancer 2004, 100:715-722.
10. Nab HW. Trends in incidence and prognosis in female breast cancer since 1955. Thesis. Erasmus University Rotterdam: Rotterdam, 1995.
11. Shapiro S, Coleman EA, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines: International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol 1998, 27:735-742.
12. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992, 340:1120-1124.
13. Guidi AJ, Berry DA, Broadwater G, et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 2000, 92:486-492.
14. Legorreta AP, Chernicoff HO, Trinh JB, et al. Diagnosis, clinical staging, and treatment of breast cancer: a retrospective multiyear study of a large controlled population. Am J Clin Oncol 2004, 27:185-190.
15. Lerouge D, Touboul E, Lefranc JP, et al. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys 2004, 59:1062-1073.
16. Mano MS, Awada A Primary chemotherapy for breast cancer: the evidence and the future. Ann Oncol 2004, 15:1161-1171.
17. Abrams JS Adjuvant therapy for breast cancer: results from the USA consensus conference. 2001. Breast Cancer 2001, 8:298-304.
18. de Koning HJ, van Ineveld BM, de Haes JC, et al. Advanced breast cancer and its prevention by screening. Br J Cancer 1992, 65:950-955.
19. Miller AB, To T, Baines CJ, et al. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000, 92:1490-1499.
20. Mittra I, Baum M, Thornton H, et al. Is clinical breast examination an acceptable alternative to mammographic screening?. BMJ 2000, 321:1071-1073.
21. Aro AR, Absetz-Ylostalo P, Eerola T, et al. Pain and discomfort during mammography. Eur J Cancer 1996, 32A:1674-1679.
22. Irwig L, Houssami N, van Vliet C New technologies in screening for breast cancer: a systematic review of their accuracy. Br J Cancer 2004, 90:2118-2122.
23. Morris EA Screening for breast cancer with MRI. Semin Ultrasound CT MR 2003, 24:45-54.
24. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427-437.
25. Teh W, Wilson AR The role of ultrasound in breast cancer screening. A consensus statement by the European Group for Breast Cancer Screening. Eur J Cancer 1998, 34:449-450.
26. Nyström L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919.
27. de Koning HJ Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003, 14:1185-1189.
28. Olsen O, Gotzsche PC. Screening for breast cancer with mammography. Cochrane Database Syst Rev: CD001877, 2001.
29. Rijnsburger AJ, van Oortmarssen GJ, Boer R, et al. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer 2004, 110:756-762.
30. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003, 361:1411-1417.
31. de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995, 87:1217-1223.
32. Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:347-360.
33. Semiglazov VF, Moiseyenko VM, Bavli JL, et al. The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad). Eur J Epidemiol 1992, 8:498-502.
34. Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002, 94:1445-1457.
35. Brekelmans CT, Collette HJ, Collette C, et al. Breast cancer after a negative screen: follow-up of women participating in the DOM Screening Programme. Eur J Cancer 1992, 28A:893-895.
36. Fracheboud J, de Koning HJ, Boer R, et al. Nationwide breast cancer screening programme fully implemented in The Netherlands. Breast 2001, 10:6-11.
37. Lynge E, Olsen AH, Fracheboud J, et al. Reporting of performance indicators of mammography screening in Europe. Eur J Cancer Prev 2003, 12:213-222.
38. Yankaskas BC, Klabunde CN, Ancelle-Park R, et al. International Comparison of Performance Measures for Screening Mammography: Can it be done?. J Med Screen 2004, 11:187-193.
39. Yen MF, Tabar L, Vitak B, et al. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003, 39:1746-1754.
40. Boer R, Warmerdam P, de Koning H, et al. Extra incidence caused by mammographic screening. Lancet 1994, 343:979.
41. de Haes JC, de Koning HJ, van Oortmarssen GJ, et al. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer 1991, 49:538-544.
42. National Expert and Training Centre for Breast Cancer Screening. Visitaties 2001-2002. Landelijk Referentiecentrum voor bevolkingsonderzoek op Borstkanker (LRCB): Nijmegen, 2003.
43. Banks E Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 2001, 8:29-34.
44. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003, 95:30-37.
45. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991, 49:531-537.
46. Brown ML, Fintor L Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat 1993, 25:113-118.
47. Beemsterboer PM, de Koning HJ, Warmerdam PG, et al. Prediction of the effects and costs of breast-cancer screening in Germany. Int J Cancer 1994, 58:623-628.
48. Groenewoud JH, Pijnappel RM, van den Akker-Van Marle ME, et al. Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. Br J Cancer 2004, 90:383-392.
49. de Koning HJ Breast cancer screening; cost-effective in practice?. Eur J Radiol 2000, 33:32-37.